VolitionRX Analyst Ratings
VolitionRX Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/21/2023 | 533.36% | EF Hutton | → $4.5 | Reiterates | Buy → Buy |
| 11/16/2023 | 251.86% | Cantor Fitzgerald | $2.1 → $2.5 | Maintains | Overweight |
| 10/30/2023 | 533.36% | EF Hutton | → $4.5 | Initiates Coverage On | → Buy |
| 08/16/2023 | 181.49% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 06/01/2023 | 744.48% | EF Hutton | → $6 | Assumes | → Buy |
| 03/16/2023 | 744.48% | EF Hutton | → $6 | Reiterates | → Buy |
| 02/01/2023 | — | Benchmark | Downgrades | Buy → Hold | |
| 12/19/2022 | 744.48% | EF Hutton | → $6 | Initiates Coverage On | → Buy |
| 08/23/2022 | 603.73% | Maxim Group | $8 → $5 | Maintains | Buy |
| 08/15/2022 | 744.48% | Aegis Capital | $9 → $6 | Maintains | Buy |
| 11/16/2021 | 1166.71% | Aegis Capital | $10 → $9 | Maintains | Buy |
| 03/10/2021 | 1025.97% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 01/25/2021 | 1307.46% | Aegis Capital | $8 → $10 | Maintains | Buy |
| 08/19/2020 | 1025.97% | Aegis Capital | $10 → $8 | Maintains | Buy |
| 05/06/2020 | 1307.46% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/21/2023 | 533.36% | EF Hutton | → 4.5 美元 | 重申 | 購買 → 購買 |
| 11/16/2023 | 251.86% | 坎託·菲茨傑拉德 | 2.1 美元 → 2.5 美元 | 維護 | 超重 |
| 10/30/2023 | 533.36% | EF Hutton | → 4.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/16/2023 | 181.49% | 坎託·菲茨傑拉德 | 3 美元 → 2 美元 | 維護 | 超重 |
| 06/01/2023 | 744.48% | EF Hutton | → 6 美元 | 假設 | → 購買 |
| 03/16/2023 | 744.48% | EF Hutton | → 6 美元 | 重申 | → 購買 |
| 02/01/2023 | — | 基準 | 降級 | 買入 → 持有 | |
| 2022 年 12 月 19 日 | 744.48% | EF Hutton | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 8 月 23 日 | 603.73% | Maxim 集團 | 8 美元 → 5 美元 | 維護 | 買 |
| 08/15/2022 | 744.48% | 宙斯盾資本 | 9 美元 → 6 美元 | 維護 | 買 |
| 11/16/2021 | 1166.71% | 宙斯盾資本 | 10 美元 → 9 美元 | 維護 | 買 |
| 03/10/2021 | 1025.97% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 1 月 25 日 | 1307.46% | 宙斯盾資本 | 8 美元 → 10 美元 | 維護 | 買 |
| 2020 年 8 月 19 日 | 1025.97% | 宙斯盾資本 | 10 美元 → 8 美元 | 維護 | 買 |
| 2020 年 6 月 5 日 | 1307.46% | 宙斯盾資本 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for VolitionRX (VNRX)?
VolitionRX（VNRX）的目標價格是多少？
The latest price target for VolitionRX (AMEX: VNRX) was reported by EF Hutton on November 21, 2023. The analyst firm set a price target for $4.50 expecting VNRX to rise to within 12 months (a possible 533.36% upside). 8 analyst firms have reported ratings in the last year.
EF Hutton於2023年11月21日公佈了VolitionRX（美國證券交易所股票代碼：VNRX）的最新目標股價。該分析公司將目標股價定爲4.50美元，預計VNRX將在12個月內升至12個月內（可能上漲533.36％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for VolitionRX (VNRX)?
分析師對VolitionRX（VNRX）的最新評級是多少？
The latest analyst rating for VolitionRX (AMEX: VNRX) was provided by EF Hutton, and VolitionRX reiterated their buy rating.
EF Hutton提供了VolitionRX（美國證券交易所股票代碼：VNRX）的最新分析師評級，VolitionRX重申了其買入評級。
When is the next analyst rating going to be posted or updated for VolitionRX (VNRX)?
VolitionRX（VNRX）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VolitionRX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VolitionRX was filed on November 21, 2023 so you should expect the next rating to be made available sometime around November 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與VolitionRx的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。VolitionRX的最新評級是在2023年11月21日公佈的，因此您應該預計下一個評級將在2024年11月21日左右公佈。
Is the Analyst Rating VolitionRX (VNRX) correct?
分析師評級 VolitionRX (VNRX) 是否正確？
While ratings are subjective and will change, the latest VolitionRX (VNRX) rating was a reiterated with a price target of $0.00 to $4.50. The current price VolitionRX (VNRX) is trading at is $0.71, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的VolitionRX（VNRX）評級，目標股價爲0.00美元至4.50美元。VolitionRX（VNRX）的當前交易價格爲0.71美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。